1. A new class of polymers: Starburst-dendritic macromolecules / D. A. Tomalia [et al.] // Polym. J. – 1985. – Vol. 17, N 1. – P. 117–132. https://doi.org/10.1295/polymj.17.117

2. Roberts, J. C. Preliminary biological evaluation of polyamidoamine (PAMAM) StarburstTM dendrimers / J. C. Roberts, M. K. Bhalgat, R. T. Zera // J. Biomed. Mater. Res. – 1996. – Vol. 30, N 1. – P. 53–65. https://doi.org/10.1002/(SICI)1097- 4636(199601)30:13.0.CO;2-Q

3. Hepatocyte targeting of 111In-labeled oligo-DNA with avidin or avidin-dendrimer complex / M. Mamede [et al.] // J. Control. Release. – 2004. – Vol. 95, N 1. – P. 133–141. https://doi.org/10.1016/j.jconrel.2003.11.015

4. Dendrimers: Relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo / N. Malik [et al.] // J. Control. Release. – 2000. – Vol. 65, N 1–2. – P. 133–148. https://doi.org/10.1016/S0168-3659(99)00246-1

5. Biodistribution characteristics of amino acid dendrimers and their PEGylated derivatives after intravenous administration / T. Okuda [et al.] // J. Control. Release. – 2006. – Vol. 114, N 1. – P. 69–77. https://doi.org/10.1016/j.jconrel.2006.05.009

6. Poly(amido)amine dendrimers generation 4.0 (PAMAM G4) reduce blood hyperglycaemia and restore impaired bloodbrain barrier permeability in streptozotocin diabetes in rats / K. Karolczak [et al.] // Int. J. Pharm. – 2012. – Vol. 436, N 1–2. – P. 508–518. https://doi.org/10.1016/j.ijpharm.2012.06.033

7. Unexpected in vivo anti-inflammatory activity observed for simple, surface functionalized poly(amidoamine) dendrimers / A. S. Chauhan [et al.] // Biomacromolecules. – 2009. – Vol. 10, N 5. – P. 1195–1202. https://doi.org/10.1021/ bm9000298

8. Evidence of oral translocation of anionic G6.5 dendrimers in mice / G. Thiagarajan [et al.] // Mol. Pharm. – 2013. – Vol. 10, N 3. – P. 988–998. https://doi.org/10.1021/mp300436c

9. Dendrimer-based postnatal therapy for neuroinflammation and cerebral palsy in a rabbit model / S. Kannan [et al.] // Sci. Transl. Med. – 2012. – Vol. 4, N 130. https://doi.org/10.1126/scitranslmed.3003162

10. Intravascular and endobronchial DNA delivery to murine lung tissue using a novel, nonviral vector / J. F. KukowskaLatallo [et al.] // Hum. Gene Ther. – 2000. – Vol. 11, N 10. – P. 1385–1395. https://doi.org/10.1089/10430340050057468

11. Low generation PAMAM dendrimer and CpG free plasmids allow targeted and extended transgene expression in tumors after systemic delivery / G. Navarro [et al.] // J. Control. Release. – 2010. – Vol. 146, N 1. – P. 99–105. https://doi. org/10.1016/j.jconrel.2010.04.030

12. Effective suicide gene therapy in vivo by EBV-based plasmid vector coupled with polyamidoamine dendrimer / H. Maruyama-Tabata [et al.] // Gene Ther. – 2000. – Vol. 7, N 1. – P. 53–60. https://doi.org/10.1038/sj.gt.3301044

13. Plasmid pORF-hTRAIL and doxorubicin co-delivery targeting to tumor using peptide-conjugated polyamidoamine dendrimer / L. Han [et al.] // Biomaterials. – 2011. – Vol. 32, N 4. – P. 1242–1252. https://doi.org/10.1016/j.biomaterials. 2010.09.070

14. Tat-BMPs-PAMAM conjugates enhance therapeutic effect of small interference RNA on U251 glioma cells in vitro and in vivo / L. Han [et al.] // Hum. Gene Ther. – 2010. – Vol. 21, N 4. – P. 417–426. https://doi.org/10.1089/hum.2009.087

15. Exploration of biomedical dendrimer space based on in-vivo physicochemical parameters: Key factor analysis (Part 2) / S. Mignani [et al] // Drug Discov. Today. ‒ 2019. ‒ Vol. 24, N 5. ‒ P. 1184–1192. https://doi.org/10.1016/j.drudis.2019.03.001.

16. Dendrimer toxicity: Let’s meet the challenge / K. Jain [et al] // Int. J. Pharm. ‒ 2010. ‒ Vol. 394, N 1–2. – P. 122–142. https://doi.org/10.1016/j.ijpharm.2010.04.027

17. Duncan, R. Dendrimer biocompatibility and toxicity / R. Duncan, L. Izzo // Adv. Drug Deliv. Rev. ‒ 2005. ‒ Vol. 57, N 15. ‒ P. 2215–2237. https://doi.org/10.1016/j.addr.2005.09.019.

18. Toxicity and surface modification of dendrimers: a critical review / R. Kharwade [et al.] // Curr. Drug Deliv. ‒ 2022. – Vol. 19, N 4. ‒ P. 451–465. https://doi.org/10.2174/1567201818666211021160441

19. In vivo toxicity of poly(propyleneimine) dendrimers / B. Ziemba [et al.] // J. Biomed. Mater. Res. A. ‒ 2011. ‒ Vol. 99, N 2. ‒ P. 261–268. https://doi.org/10.1002/jbm.a.33196

20. In vivo therapeutic applications of phosphorus dendrimers: State of the art / S. Mignani [et al.] // Drug Discov. Today. ‒ 2021. ‒ Vol. 26. ‒ P. 677‒689. https://doi.org/10.1016/j.drudis.2020.11.034